Home › Funds › DCVC Opportunity Fund II GP, LLC › RXRX

DCVC Opportunity Fund II GP, LLC position in RXRX

RECURSION PHARMACEUTICALCLASS A · Health Care

DCVC Opportunity Fund II GP, LLC reported holding 3,951,141 shares of RXRX (RECURSION PHARMACEUTICALCLASS A) in its Q2 2026 13F filing — a position valued at US$14.5M, representing 84.30% of its reported portfolio and ranking #1 among its reported holdings. DCVC Opportunity Fund II GP, LLC has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)3.95M sh
Reported value held$14.50M
Portfolio Weight84.30%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DCVC Opportunity Fund II GP, LLC's RXRX position evolved

DCVC Opportunity Fund II GP, LLC first disclosed a stake in RXRX in Q4 2023 at 3,951,141 shares (US$39.0M). The position peaked in Q1 2024 at 3,951,141 shares, worth US$39.4M. Across 11 filings, DCVC Opportunity Fund II GP, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 3,951,141 shares valued at US$14.5M.

Quarter by quarter

QuarterSharesValueChange
Q4 2023 3.95M $38.96M New
Q1 2024 3.95M $39.39M Hold
Q2 2024 3.95M $29.63M Hold
Q3 2024 3.95M $26.04M Hold
Q4 2024 3.95M $26.71M Hold
Q1 2025 3.95M $20.90M Hold
Q2 2025 3.95M $19.99M Hold
Q3 2025 3.95M $19.28M Hold
Q4 2025 3.95M $16.16M Hold
Q1 2026 3.95M $12.13M Hold
Q2 2026 3.95M $14.50M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RXRX and 13F data

RXRX (RECURSION PHARMACEUTICALCLASS A) is a Health Care company. 28 other funds we track also report a position in RXRX — the largest reported positions include ARK Invest (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RXRX

All RXRX fund holders →

FAQ

How long has DCVC Opportunity Fund II GP, LLC held RXRX?

DCVC Opportunity Fund II GP, LLC has disclosed RXRX holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is DCVC Opportunity Fund II GP, LLC's current position in RXRX?

As of Q2 2026, DCVC Opportunity Fund II GP, LLC holds 3.95M shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $14.50M, representing 84.30% of its reported portfolio and ranking #1.

Has DCVC Opportunity Fund II GP, LLC been buying or selling RXRX?

In the latest 13F filing (Q2 2026), DCVC Opportunity Fund II GP, LLC held unchanged its position in RXRX. The position peaked in Q1 2024 at 3.95M shares.

Which other funds hold RXRX?

Other major institutional holders of RXRX include ARK Invest, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.